Contrary to those results, in a previous study by our group and the present study, we found diminished expression rates for the mBCMA receptor on CD19+ B cells from SLE patients, as this expression was almost null in patients with severe disease. This evidence concerns the gene CD19 and systemic lupus erythematosus.